A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508556-18-00

Acronym

CCHF-NP-1

Enrollment

Registered

2024-05-03

Start date

2024-09-25

Completion date

Unknown

Last updated

2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crimean Congo Hemorrhagic Fever

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026